Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics' stock price has experienced a significant decline over the past year. Key events impacting the stock include earnings reports, analyst downgrades, clinical trial updates, and FDA designations. The company reported its Q4 2024, Q1 2025, and Q2 2025 earnings, with the Q2 2025 net loss beating expectations. J.P. Morgan and Wall Street Zen downgraded Allogene Therapeutics to a Sell rating in October 2025. The company presented updated Phase 1 data for ALLO-316 and announced moving forward with a standard lymphodepletion regimen in the ALPHA3 trial for cema-cel. Allogene was granted three U.S. FDA Fast Track Designations for ALLO-329.

There is no indication of significant demand seasonality for Allogene Therapeutics' products and services. The need for these therapies is driven by disease incidence and progression, clinical trial progress, and potential regulatory approvals, rather than seasonal patterns. The market for allogeneic T-cell therapies is projected to grow steadily, driven by factors such as expanding indications, rising demand for cell-based immunotherapies, and increasing awareness.

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. The company is dedicated to creating "off-the-shelf" AlloCAR T™ products to overcome the complexities of autologous CAR T therapies. Its pipeline includes AlloCAR T products such as Cemacabtagene Ansegedleucel (cema-cel) for hematologic malignancies, ALLO-316 for CD70+ heme malignancies and solid tumors, ALLO-329 for autoimmune diseases, and UCART19 for relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia (ALL). Other pipeline candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-647, ALLO-819, and DLL3.

Allogene Therapeutics is headquartered in South San Francisco, California, USA, which serves as the central hub for its operations. The company's global presence is characterized by multi-center clinical trials across North America, Europe, and potentially other regions. Allogene also engages in global collaborations for research and technology access.

Allogene Therapeutics maintains a reputation as a pioneering clinical-stage biotechnology company focused on developing allogeneic CAR T cell therapies. The company is recognized for its strategic differentiation through platform innovation and pipeline diversification. Positive developments include the expansion of its partnership with Foresight Diagnostics, receiving U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316, and presenting promising Phase 1 TRAVERSE trial data for ALLO-316. However, the company's reputation has faced challenges due to market skepticism, analyst downgrades, and a patent lawsuit involving its licensor, Cellectis.

Allogene Therapeutics' stock is primarily owned by institutional shareholders, who hold 82.76% of the company. Major institutional owners include Pfizer Inc, TPG Gp A, Llc, BlackRock, Inc., SMCWX - SMALLCAP WORLD FUND INC Class A, Capital World Investors, Lynx1 Capital Management LP, Darwin Global Management, Ltd., Citadel Advisors Llc, Vanguard Group Inc, Primecap Management Co/ca/, Invesco Ltd., Virtus Investment Advisers LLC, Quadrature Capital Ltd, Foresite Capital Management VI LLC, Goldman Sachs Group Inc., T. Rowe Price Group, Inc., and State Street Global Advisors, Inc. Pfizer Inc. is the largest individual shareholder, owning 9.93% of the company, and CEO David Chang owns 3.8% of the company's shares.